Amicus Therapeutics’ Expanded Portfolio Includes Potential Gene Therapies for Batten Disease
News
Amicus Therapeutics has gained global development and commercial rights to 10 gene therapy programs for lysosomal storage disorders, including three potential first-to-market therapies for Batten disease. This pipeline expansion resulted from ... Read more